(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	AL
OMB Number:	3235-0287
Estimated average burd	en
hours per response	0.5
	OMB Number: Estimated average burd

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person Maynard Ryan D					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 01/31/2007							X Officer (give title below) Other (specify below) VP, CFO					
(Street)				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fo	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
SOUTH	SAN FRA	NCISCO, CA 94	4080									iiii iiicd by ivio	re man One Rep	orting reison			
(Ci	ty)	(State)	(Zip)				Tal	ole I - Non-	Deriva	tive Securities	Acquired, l	Disposed of	, or Benefic	ially Owned			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Y	ear) Exe			Coc (Ins	3. Transaction Code (Instr. 8)		or Disposed of tr. 3, 4 and 5)	(D) Owne Transa	Owned Following Transaction(s)		O Fo	wnership of orm: Be	Beneficial		
				(M	onth	nth/Day/Year)		Code V	/ Am	(A) or ount (D)	(Instr.	(Instr. 3 and 4)		or (I	Indirect (In	wnership nstr. 4)	
			Table					curicquired, D	ently	are not required to the control of t	ntrol numb	er.	s the form	displays a			
	2. Conversion or Exercise Price of Derivative Security		Execution Date, if Transaction Derivative Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (Do or Indirect (I)	(Instr. 4)							
				Code	v	(A)	(D)	Date Exercisab	le	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock Option (right to buy)	\$ 11.73	01/31/2007		A		106,911		02/01/20)07 ⁽¹⁾	01/31/2017	Common Stock	106,911	\$ 0	106,911	D		

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Maynard Ryan D RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			VP, CFO				

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	02/01/2007
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The shares vest monthly over one (1) year from 01/01/07.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.